Want to join the conversation?
$BIIB's 3Q15 global TECFIDERA revenue was up 19% YoverY at $937MM and Interferon revenues was up 5% at $785MM. On the contrary, TYSABRI global revenue was $480MM, down 4% YoverY. ALPROLIX reported revenue of $66MM and ELOCTATE revenue was at $91MM.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.